Press Releases Items Per Page 102550 Year None2018201720162015201420132012201120102007 10.17.17 Syndax Announces $25 Million Registered Direct Offering of Common Stock 10.17.17 Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors 10.05.17 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin 09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference 08.30.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences 08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update 08.03.17 Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017 07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 05.24.17 Syndax Prices Public Offering of Common Stock 05.23.17 Syndax Announces Proposed Public Offering of Common Stock 05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma 05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
10.17.17 Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors
10.05.17 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference
08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update
08.03.17 Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017
07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy
05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies
